Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
about
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role.Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers.Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancerA joint analysis of metabolomics and genetics of breast cancer.Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyWSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigaFlax and Breast Cancer: A Systematic Review.Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.Ki-67/MIB-1 immunostaining in a cohort of human gliomas.Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients.Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyImmunohistochemistry and mass spectrometry for highly multiplexed cellular molecular imaging.Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.Unmanipulated native fat exposed to high-energy diet, but not autologous grafted fat by itself, may lead to overexpression of Ki67 and PAI-1.Pathological features of transplanted tumor established by CD133 positive TJ905 glioblastoma stem-like cellsDifferences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013Fusion with stem cell makes the hepatocellular carcinoma cells similar to liver tumor-initiating cells.Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast CancersPredictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer.Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort studyInterface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells.Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast CancerInterobserver Variability of Ki-67 Measurement in Breast Cancer.The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.The nucleolar protein NIFK promotes cancer progression via CK1α/β-catenin in metastasis and Ki-67-dependent cell proliferationDetermination of whole transcription profiles and specific pathways in invasive ductal breast carcinomaBeing Overweight or Obese Increases the Risk of Progression in Triple-Negative Breast Cancer after Surgical Resection.Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryTranscriptome sequencing uncovers a three-long noncoding RNA signature in predicting breast cancer survival.Complement component 1, q subcomponent binding protein is a marker for proliferation in breast cancer.Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation.Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study
P2860
Q30543788-EED92666-5749-42F8-AFE9-4481AC082679Q30652903-979A451A-1398-4D58-AF32-395C323B37D5Q33591751-068D4EB7-5A5A-4BDC-AC67-B59B37DC46CDQ33624177-1FF79721-2357-40C4-8F2B-666CCA293232Q33843751-24122112-EF72-4EFB-9216-27E4722249B3Q33915010-7ABFC71E-7BC7-4041-A542-983397BB4676Q34174466-3FF370E6-D768-416A-BE90-918387B46652Q34296486-CF79C5C3-049C-49B6-B1DC-61FCE4B38CD0Q34348721-3A94A1B3-8B50-48AD-829F-148082FC2640Q34567461-745E9C4A-D160-4F6A-BFA5-4084C177F937Q34956588-964FADE8-7F80-4251-9B79-7D2DC43E96CCQ34980961-0846E6EF-E9D4-4229-BE99-B0C7701F60B0Q35021646-B250D594-D43E-4CE4-9DCD-77033252E28DQ35038363-5A60C852-8F17-4267-A28B-E2239BA01659Q35042063-0AC34308-C9DB-4E3A-ABB9-A6A8512702BFQ35462377-62126F94-420D-4760-AB4A-E61FEE5CA6BFQ35570005-CDAD9D6D-6CB5-473F-93CE-62E9554D219FQ35583876-D26DD6B1-8AB6-4304-B23A-CEF11FA91534Q35709269-B7BE571E-D8EF-44CA-BB9F-B019E51EA482Q35752791-40F1D960-4119-4212-9208-2359F66A0F53Q35804059-B57B458F-F0D5-44B3-925D-DCC8F6C801D0Q35813033-A2D0CB49-BCB1-4A23-96B6-4452C7916249Q35914875-0430EE21-DAEF-4C3A-8595-E0D4C47AB470Q35949292-FAD77BAA-F9F6-4427-9955-36565F5757DEQ36133814-9D261A85-0FF4-4E07-966A-68FAD672A1B5Q36135274-B125467D-6C9C-4EAA-ADE7-8205E5B753A7Q36277239-997FBD5C-D7A3-46AF-9845-C024D794E37DQ36279137-E003D2FB-AF91-43E7-9BDF-091911567883Q36558409-85EB4C14-AD66-4215-A89E-0EB638CCE86BQ36719073-EF336BF1-3A4F-43FE-9EA0-10A24569A6B1Q36732425-2C56204E-75E4-45EB-83A3-C0CE31EFC746Q36739734-D75BBCD0-2306-4DB5-820D-61DEAA2B69A4Q36853431-D55AD1CA-6A97-4624-AA44-48C4D654AD10Q36859845-A3D15B5C-BAA9-4848-9F6E-AC43F379CE9CQ36892788-000FB28D-A67E-44FD-8EB0-01BBBEB46E19Q37034875-00ECD821-D269-4CE9-961C-C9026525C03EQ37071560-15719B0B-B79D-4FD9-B0B1-5285FEF5A823Q37096479-A7DC3F1F-9B8B-449F-9B03-238EE9CAB001Q37114482-AC58A54D-351E-4371-932C-8725839235C3Q37153412-93DC0A88-8B3A-4D78-8E7C-64C92DE0A711
P2860
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Ki-67: level of evidence and m ...... analytical and critical review
@ast
Ki-67: level of evidence and m ...... analytical and critical review
@en
type
label
Ki-67: level of evidence and m ...... analytical and critical review
@ast
Ki-67: level of evidence and m ...... analytical and critical review
@en
prefLabel
Ki-67: level of evidence and m ...... analytical and critical review
@ast
Ki-67: level of evidence and m ...... analytical and critical review
@en
P2093
P2860
P50
P921
P1476
Ki-67: level of evidence and m ...... analytical and critical review
@en
P2093
Alain Fourquet
Anne Gompel
Brigitte Sigal-Zafrani
Bruno Poulet
Carole Mathelin
Caroline Egele
Daniel Serin
Elisabeth Luporsi
Etienne Brain
Frédérique Spyratos
P2860
P2888
P304
P356
10.1007/S10549-011-1837-Z
P407
P50
P577
2011-11-03T00:00:00Z
2012-04-01T00:00:00Z